Regen BioPharmaRGBP Return-on-Tangible-Asset is 1,596.78% as of Mar. 2026. The stock has 7 warning signs investors should review. Among 1,413 Biotechnology companies, Regen BioPharma ranks worse than 95.12% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Regen BioPharma's annualizedNet Income for the quarter that ended in Mar. 2026 was $3.97 Mil. Regen BioPharma's average total tangible assets for the quarter that ended in Mar. 2026 was $0.25 Mil. Therefore, Regen BioPharma's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 1,596.78%.
The historical rank and industry rank for Regen BioPharma's Return-on-Tangible-Asset or its related term are showing as below:
RGBP'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -1703.25 Med: -701.37 Max: 2461.26
Current: -314.15
During the past 13 years, Regen BioPharma's highest Return-on-Tangible-Asset was 2461.26%. The lowest was -1703.25%. And the median was -701.37%.
RGBP's Return-on-Tangible-Asset is ranked worse than 95.12% of 1413
companies
in the Biotechnology industry
Industry Median: -35.57
vs RGBP: -314.15
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Regen BioPharma Return-on-Tangible-Asset Related Terms
Regen BioPharma Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Regen BioPharma's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGBP vs SIGY, ENDV, CNBX: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Regen BioPharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regen BioPharma Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regen BioPharma's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Regen BioPharma's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 1,596.78% mean?
Regen BioPharma (RGBP) has a Return-on-Tangible-Asset of 1,596.78% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Regen BioPharma and its competitors. According to the industry distribution chart, Regen BioPharma ranks #1344 out of 1413 companies in the Biotechnology industry, placing it in the top 95.1%.
Is Regen BioPharma's Return-on-Tangible-Asset too high?
Regen BioPharma's current Return-on-Tangible-Asset is 1,596.78%. Based on the distribution chart, Regen BioPharma ranks #1344 out of 1413 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Regen BioPharma's Return-on-Tangible-Asset compare to SIGY and ENDV?
According to the Biotechnology industry distribution chart, Regen BioPharma ranks #1344 out of 1413 companies for Return-on-Tangible-Asset. This places Regen BioPharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Regen BioPharma and its competitors. Regen BioPharma's current Return-on-Tangible-Asset is 1,596.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99.5% below its estimated fair value. The current Return-on-Tangible-Asset is 1,596.78%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current Return-on-Tangible-Asset is 1,596.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGBP has been successfully added to your 